GeneCopoeia Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus
GeneCopoeia’s Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus products are designed to produce a specially packaged variant of standard lentivirus that replaces VSV-G envelope glycoprotein with the Spike (S) protein.
The company’s spike-pseudotyped lentivirus can be used for several applications, such as: vaccine development for the SARS-CoV-2 virus; studying the efficacy and mechanism of neutralising antibodies against the SARS-CoV-2 virus; development of antiviral therapeutic agents; and studying the mechanism of virus-receptor interaction.
In addition to lentiviral particles, GeneCopoeia also offers a SARS-CoV-2 Spike Protein Pseudotyped Lentivirus Particle Kit that includes all required reagents: Lentifect SARS-CoV-2 Spike protein-pseudotyped lentiviral particles; Lentifect Standard VSV-G lentiviral particles; and the company’s ACE2-expressing HEK293T cell line.
For more information: https://www.genecopoeia.com/product/lentifect-sars-cov-2-spike-pseudotyped-lentivirus/.
Phone: 02 4575 0309
Cayman Chemical LipidLaunch Ionizable Lipid LNP Screening Set
The LipidLaunch Ionizable Lipid LNP Screening Set is a screening set of 12 ionisable cationic and...
Antibodies.com neutrophil marker antibodies
Antibodies.com offers a variety of markers that identify neutrophils at various stages of...
TRC stable isotope labelled (SIL) compounds
TRC's high-quality stable isotope labelled (SIL) compounds are important tools for...
Learn More
I am interested in GeneCopoeia Lentifect SARS-CoV-2 Spike-pseudotyped lentivirus.
Complete the form and a supplier representative will be in touch.
